Phaseline

Companies › Genelux

Genelux: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Olvimulogene nanivacirepvec
Engineered oncolytic vaccinia virus
–Phase 3Platinum-resistant Ovarian Cancer; Advanced Non-squamous Non-small-cell Lung CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05281471Olvimulogene nanivacirepvecPhase 3Platinum-resistant Ovarian CancerOncologyDec 2026
NCT06463665Olvimulogene nanivacirepvecPhase 2Advanced Non-squamous Non-small-cell Lung CancerOncologyFeb 2027

From the company's SEC filings

Cash and short-term investments of $19m on 2026-06-30; operating cash outflow about $25m a year; runway about 9 months at that burn, to Mar 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Imunon BriaCell Therapeutics Actinium Pharmaceuticals Oncolytics Biotech Cardiff Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.